Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Managment of Acute Myeloid Leukemia and Myelodysplastic Patients Relapsing After Allogenic Stem Cell Transplantation: Results of the GITMO AML/MDS-relapse Registry Study

NCT06790680 is registered in ClinicalTrials.gov with Gruppo Italiano Trapianto di Midollo Osseo as lead sponsor.

NCT NCT06790680
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06790680 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Managment of Acute Myeloid Leukemia and Myelodysplastic Patients Relapsing After Allogenic Stem Cell Transplantation: Results of the GITMO AML/MDS-relapse Registry Study
Lead sponsor
Gruppo Italiano Trapianto di Midollo Osseo
Phase
Observational
Overall status
Completed
Start date
December 15, 2022
Completion date
May 9, 2024
Enrollment
859 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

acute myeloid leukaemia, myelodysplastic syndrome